The estimated Net Worth of Jeremy Blank is at least $633 mil dollars as of 9 March 2023. Jeremy Blank owns over 154,293 units of Gamida Cell Ltd stock worth over $15,617 and over the last 2 years Jeremy sold GMDA stock worth over $617,172.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jeremy Blank GMDA stock SEC Form 4 insiders trading
Jeremy has made over 2 trades of the Gamida Cell Ltd stock since 2023, according to the Form 4 filled with the SEC. Most recently Jeremy sold 154,293 units of GMDA stock worth $617,172 on 9 March 2023.
The largest trade Jeremy's ever made was buying 631,866 units of Gamida Cell Ltd stock on 1 February 2023 worth over $2,527,464. On average, Jeremy trades about 157,232 units every 7 days since 2023. As of 9 March 2023 Jeremy still owns at least 477,573 units of Gamida Cell Ltd stock.
You can see the complete history of Jeremy Blank stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jeremy Blank's mailing address?
Jeremy's mailing address filed with the SEC is C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON, MA, 02116.
Insiders trading at Gamida Cell Ltd
Over the last 3 years, insiders at Gamida Cell Ltd have traded over $0 worth of Gamida Cell Ltd stock and bought 85,483 units worth $132,499 . The most active insiders traders include Stephen T Wills, Robert I Blum y Jeremy Blank. On average, Gamida Cell Ltd executives and independent directors trade stock every 0 days with the average trade being worth of $699. The most recent stock trade was executed by Stephen T Wills on 30 September 2022, trading 9,677 units of GMDA stock currently worth $14,999.
What does Gamida Cell Ltd do?
gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.
What does Gamida Cell Ltd's logo look like?
Complete history of Jeremy Blank stock trades at Advanced Emissions Solutions Inc y Gamida Cell Ltd
Gamida Cell Ltd executives and stock owners
Gamida Cell Ltd executives and other stock owners filed with the SEC include:
-
Julian Adams,
Chief Executive Officer, Director -
Ronit Simantov,
Chief Medical Officer -
Joshua Hamermesh,
Chief Business Officer -
Shai Lankry,
Chief Financial Officer -
Thomas Klima,
Chief Commercial Officer -
Dr. Julian Adams Ph.D.,
CEO & Director -
Dr. Ronit Simantov M.D.,
Chief Medical Officer -
Joshua D. Hamermesh MBA,
Chief Bus. Officer -
Dr. Jas Uppal,
Chief Regulatory & Quality Officer -
Shai Lankry CPA, M.B.A.,
Chief Financial Officer -
Jaren Madden,
Vice President of Investor Relations and Corporate Communications -
Michael Perry,
Non-Executive Independent Director -
Kenneth Moch,
Non-Executive Independent Director -
Ofer Gonen,
Non-Executive Independent Director -
Nurit Benjamini,
Non-Executive Independent Director -
stephen Wills,
Independent Director -
Shawn Tomasello,
Independent Director -
David Fox,
Independent Director -
Jas Uppal,
Chief Regulatory and Quality Officer -
Tracey Lodie,
Chief Scientific Officer -
Tzvi Palash,
Chief Operating Officer -
Robert Blum,
Non-Executive Independent Chairman of the Board -
Joshua F. Patterson,
Gen. Counsel -
Naftali Brikashvili CPA,
Sr. VP Fin. & Operations -
Matthew Metivier,
VP of Human Resource -
Paul Nee,
VP of Marketing -
Michele Ilene Korfin M.B.A., R.Ph.,
Chief Operating & Chief Commercial Officer -
Jeremy Blank,
Director -
Naama Halevi Davidov,
Director -
Anat Cohen Dayag,
Director -
Michele Ilene Korfin,
COO/CHIEF COMMERCIAL OFFICER -
Ivan M. Borrello,
-
Abigail L. Jenkins,
President and CEO -
Joshua F. Patterson,
GENERAL COUNSEL -
Mary Theresa Coelho,
Chief Financial Officer